Thursday, October 17, 2019
Posted by: Natasha Azar
ArsenalBio launched with an $80M Seed financing syndicated by Westlake Village BioPartners, Kleiner Perkins, PICI, and the UCSF Foundation with participation from OUP. Founded in 2018, Arsenal is developing cellular drug discovery tools intended to provide medicines for cancer treatment. The company was founded based on work by Alex Marson of UC San Francisco, E. John Wherry of University of Pennsylvania, Nick Haining of Dana-Farber, and Brad Bernstein of Harvard University.
Arsenal’s novel approach can directly edit the genome of a patient’s impaired immune system cells in vitro with an automatable process that increases the breadth, accuracy, and complexity of value-added genome edits (e.g., added potency, resistance to tumor evasion, increased tumor killing, reduction in toxicity) while dramatically reducing the current standards for COGS and CAPEX, and potentially the reverse logistics of central manufacturing. Arsenal’s core technology is a proprietary non-viral DNA delivery process, exclusively licensed from UCSF, exhibiting a capacity to deliver rising amounts of DNA into human cells at declining cost per kilobase. Arsenal has also licensed IP from Dana-Farber Cancer Institute and University of Pennsylvania. More here.